Interruption of investigational drug supplies due to political instability at overseas contractors
First written in FY2023. 1 of 2 entries say "Restated". Latest entry: FY2025.
4 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「We outsource the manufacture, storage and other activities related to clinical trial drugs for the drug candidates we are developing to overseas companies. We have selected potential contractors in multiple countries to mitigate these risks. However, if political instability or another such event occurs in a country where we have outsourced these activities, the supply of clinical trial drugs could be interrupted, potentially affecting our operating results and financial condition.」
The company has reconfirmed the risk of clinical trial drug supply interruptions due to political instability in countries where overseas contractors are located, as well as its response of selecting potential contractors in multiple countries. - FY2023First statedAnnual report
「We outsource the manufacture, storage and other activities related to clinical trial drugs for the drug candidates we are developing to overseas companies. We have selected potential contractors in multiple countries to mitigate these risks. However, if political instability or another such event occurs in a country where we have outsourced these activities, the supply of clinical trial drugs could be interrupted, potentially affecting our operating results and financial condition.」
The company has disclosed for the first time the risk of supply interruptions due to political instability in countries where clinical trial drug manufacturing and storage are outsourced, as well as its response of selecting potential contractors in multiple countries.